Roche Begins Phase I Trial of Subcutaneous Formulation With Enhanze

Halozyme Therapeutics, Inc. announced that Roche has dosed the first patient in a Phase 1 pharmacokinetic clinical trial with a subcutaneous formulation using Enhanze Technology of a biologic directed to a second Roche exclusive target.
TradingMarkets